Chicago Capital LLC Makes New Investment in NeoGenomics, Inc. (NASDAQ:NEO)

Chicago Capital LLC bought a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,380 shares of the medical research company’s stock, valued at approximately $270,000.

Several other large investors also recently modified their holdings of the stock. Loomis Sayles & Co. L P acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at $17,807,000. Segall Bryant & Hamill LLC boosted its stake in NeoGenomics by 67.0% in the third quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company’s stock valued at $27,928,000 after buying an additional 759,524 shares in the last quarter. Bellevue Group AG grew its position in NeoGenomics by 34.2% in the third quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company’s stock valued at $23,786,000 after acquiring an additional 410,516 shares during the last quarter. State Street Corp raised its stake in NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock worth $73,139,000 after acquiring an additional 80,449 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of NeoGenomics in the third quarter worth about $1,101,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. This represents a 12.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company’s stock.

NeoGenomics Trading Down 2.9 %

Shares of NEO stock opened at $13.88 on Tuesday. NeoGenomics, Inc. has a 1-year low of $12.13 and a 1-year high of $19.11. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -22.75 and a beta of 1.23. The stock has a 50-day moving average of $16.46 and a 200-day moving average of $15.70.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The business had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.06) EPS. On average, equities research analysts forecast that NeoGenomics, Inc. will post -0.16 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a report on Friday, January 10th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target for the company. Bank of America increased their price target on NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. The Goldman Sachs Group reduced their price objective on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, NeoGenomics has an average rating of “Moderate Buy” and a consensus price target of $20.20.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.